Alembic Pharma plans to launch 25 drugs in US generics segment this fiscal

The Vadodara-based drug maker, which has been around for over a century, is a late entrant in the US market. It has more than made up for it. It has been on an investment overdrive, spending about ₹700-₹750 crore per annum on R&D to build a complex pipeline of products for the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HcPbiTm
via IFTTT